NEW YORK (360Dx) – The Foundation for Innovative New Diagnostics today announced that it is awarding funding to support the development, manufacture, and feasibility testing of two prototype core antigen (cAg) immunoassays for confirmatory hepatitis C virus diagnosis at the point of care.

Financial terms of the awards were not disclosed.